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The aims of study were to investigate the effects of intraperitoneal (i.p.) infusion of ghrelin on pancreatic α-amylase
outputs and the responses of pancreatic proteins to ghrelin that may relate to the pancreatic exocrine. Six male
Sprague-Dawley rats (300 g) were randomly divided into two groups, a control group (C, n = 3) and a treatment
group (T, 10.0μg/kg BW, n = 3). Blood samples were collected from rat caudal vein once time after one hour
injection. The concentrations of plasma ghrelin, cholecystokinin (CCK) and alfa-amylase activity were evaluated by
enzyme immunoassay (EIA) kit. Two-dimensional gel electrophoresis (2-DE) analysis was conducted to separate the
proteins in pancreas tissue. Results showed that the i.p. infusion of ghrelin at doses of 10.0 μg/kg body weight (BW)
increased the plasma ghrelin concentrations (p = 0.07) and elevated the plasma CCK level significantly (p < 0.05).
Although there was no statistically significant, the α-amylase activity tended to increase. The proteomics analysis
indicated that some pancreatic proteins with various functions were up- or down- regulated compared with control
group. In conclusion, ghrelin may have role in the pancreatic exocrine, but the signaling pathway was still not clear.
Therefore, much more functional studies focus on these found proteins are needed in the near future.
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Two-dimensional gel electrophoresisBackground
Ghrelin is a 28-amino-acid peptide isolated from the rat
stomach in 1999 which is mainly produced by X/A-like
cells in the oxyntic mucosa [1]. It was also found in other
parts like hypothalamus, pituitary gland, lung, kidney [2-4],
duodenum, ileum, colon and pancreas [5]. The ghrelin re-
ceptors (GHS-R) have been detected in many central and
peripheral tissues and pancreatic α-cells, β-cells, exocrine
cells. Ghrelin shows a number of actions at the gastrointes-
tinal tract level. It is well known as a stronger activator of
growth hormone (GH) through central nervous system
(CNS) and modulation of food intake. And it also exhibits
lots of other biological activities including energy expend-
iture, stimulation of lactotroph and corticotroph secretion,* Correspondence: hglee66@konkuk.ac.kr
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unless otherwise stated.influence on sleep and behavior or modulation of heart rate
and blood pressure ([6-9]; Assakawa et al. [10]).
Recent studies demonstrated that ghrelin could modulate
exocrine secretions as well as pancreatic endocrine secre-
tions. There were two opposite theories. First, Zhang and
coworkers demonstrated that intravenous administration of
ghrelin to the rats produced inhibition of enzyme secretion,
and that this inhibitory effect of ghrelin on pancreatic exo-
crine secretion is indirect and may be exerted at the level of
intrapancreatic neurons [11]. In contrast, other studies re-
vealed that central as well as peripheral administration of
ghrelin significantly increased pancreatic fluid and protein
output, though the activation of vagal centers in the brain-
stem and stimulation of vagal efferent nerves [12,13]. It is
generally believed that, in the intestinal phase, stimulation
of pancreatic enzyme secretion depends, in the main part,
on the neuronal mechanism involved in the CCK release
and activation of cholinergic vago-vagal enteropancreatic
reflex. However, these physiological roles of ghrelin in the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Relationship between plasma G.I. hormones and
α-amylase activity
Items Ghrelin (ng/ml) CCK (ng/ml) α-amylase (U/L)
Control1 0.202 ± 0.1522* 5.745 ± 2.428 3791.799 ± 208.308
Treatment1 3.223 ± 2.140 11.306 ± 3.937 4210.847 ± 262.825
1Control = vehicle/500 uLSaline, Treatment = Ghrelin (10.0 ug/kg)/500 uLSaline.
2Data are mean ± SEM and *means significantly different, p < 0.05 (Student’s
paired t-test).
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unclear (Gherlaldoni et al. [14]).
Therefore, this study was conducted to determine
the effects of exogenous ghrelin, given intraperitoneal
(i.p.) on plasma CCK level and α-amylase output in the
sprague-dawley rats. Meanwhile, the responses of pan-




Rat ghrelin peptide was obtained from Bachem (Bubendorf,
Switzerland). Rat plasma ghrelin and CCK enzyme immuno-
assay kit were purchased from Phoenix Pharmaceuticals
(Mountain View, CA, USA). The α-amylase activity analyzed
using an EnzyChrom™ a-Amylase Assay Kit (ECAM-100).
Animals
Sprague-Dawley rats (300 g) (Samtaco, Osan, Korea) were
used for all experiments. Animals were housed at one ani-
mal per cage on a 12/12 h light cycle (lights on at 8 am)
and given access to food and water ad libitum. Ghrelin (0.1,
1.0, 10.0 ug/kg, respectively) were injected intraperitoneally
in rats. One hour after injection, blood samples (1 ml) were
collected from rat caudal vein once time into heparined
tube and immediately centrifuged (3,000 rpm/min, 15 min)
to obtain the plasma. Aliquots of plasma were stored
at -80°C till analyzed. Then rats were anaesthetized via
intramuscular injection of zoletil (Vetbutal) at a dose
of 15.0 mg/300 g (BW). And the rat pancreas tissues were
collected. All experimental procedures were in accordance
with the “Guidelines for the Care and Use of Experimental
Animals of Pusan National University”.
Determination of plasma ghrelin, CCK concentration and
α-amylase activity
The plasma ghrelin and CCK concentration were separ-
ately determined by enzyme immunoassay kit (Phoenix
Pharmaceuticals, Inc., Burlingame, CA, USA). The plasma
α-amylase activity analyzed using an EnzyChrom™
a-Amylase Assay Kit (ECAM-100, BioAssay Systems,
Hayward, CA, USA). All the operations were done followed
the kit manual.
Pancreas sample preparation and 2-DE analysis
Pancreatic tissues were collected and then pulverized into
powder under liquid nitrogen and stored at -80°C until use.
Tissues (0.5 g) were homogenized in 1ml lysis solution
containing 7 M urea, 2 M thiourea, 4% chaps, 40 mM Tris,
65 mM DTT, 0.5% IPG buffer and 1X protease inhibitor
(GE Healthcare, Piscataway, New Jersey, USA). This mix-
ture was stirred every 5 min for 30 min and then centri-
fuged at 14,000 rpm for 30 min at 20°C. The supernatant
was then stored in aliquots at -80°C until analysis.2-DE was performed of pooling pancreatic tissue samples
from three animals in each group. Briefly, protein samples
were diluted into isoelectric focusing (IEF) buffer contain-
ing 6 M urea, 2 M thiourea, 1% 3-((3-Cholamidopropyl)
dimethylammonium)-1-propanesulfonate (CHAPS), 0.002%
bromophenol blue, 0.5% phamalyte (pH 3-10NL) and 65
mM dithiothreitol (DTT). Then 100 μg protein smaples of
control or treatment was loaded on Immobiline DryStrip
gels (pH 3-10NL, 18 cm, GE Healthcare) for rehydration
for 12 h at 20°C. The IEF procedures were performed using
an IEF electrophoresis unit (GE Healthcare) following the
manufacturer’s protocols. The following voltage program
was used after the 12 h rehydration: linear ramp from 500
to 1000 V over 2 h, then a constant voltage of 8000 V for 7
h to give a total of 56,000 V h. After focusing, gel strips
were equilibrated in a solution containing 50 mM Tris/HCl
(pH 8.8), 6 M urea, 2% SDS, 30% glycerol, 0.002% w/v bro-
mophenol blue and DTT for 15 min, followed by incuba-
tion in the same solution but replacing DTT with 135 mM
iodoacetamide (IAA) for another 15 min. After that the
equilibrated strips were inserted into sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels
(18 cm, 12%). SDS-PAGE was performed using an Ettan
DALT 2-D gel system (GE Healthcare). Upon completion,
gels were stained using a PluseOne Silver Staining Kit
(GE Healthcare). The silverstained gels were scanned
using an Umax scanner (PowerLook 2100XL, UMAX
Technologies, Inc., Dallas, TX, USA). Scanned gel images
were processed by Proteomweaver™ 2-D Analysis Software
(Definiens AG, Munich, Germany).
Statistical analysis
Data are presented as mean ± standard error of the mean
(SEM). The group mean values were compared with an
independent sample t-test (SPSS 14.0, Chicago, IL, USA). A
p-value <0.05 was considered to be statistically significant.
Results and discussion
The i.p. infusion of ghrelin at doses of 10.0 μg/kg body
weight (BW) increased the plasma ghrelin concentrations
(p = 0.07) and elevated the plasma CCK level significantly
(p < 0.05). Although there was no statistically significant,
the α-amylase activity tended to increase (Table 1). These
data indicated that ghrelin may have role in pancreatic exo-
crine secretion through the stimulation of CCK release and
Figure 1 Representative silver-stained 2-DE images of the normal rat pancreas (left) and treated rat pancreas by Ghrelin (right).
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gut hormones which released from duodenal mucosa I
cells. It can stimulate pancreatic exocrine secretion via
activation of CCK1 receptors and entero-pancreatic
vago-vagal reflex [15-19]. Whether CCK plays a role in
the exocrine secretion response to ghrelin is unknown.Table 2 Identification of differentially altered protein spots in
Spot Protein name Peptide matc
Cell growth and proliferation
8109 Eukaryotic translation initiation factor 5A-1 295
Gluconeogenesis
9071 Malate dehydrogenase, mitochondrial precursor 40
De nove purine biosynthesis
9447 Similar to adenylosuccinate lyase 67
Oxidative stress
6858 PRx IV 44
7120 Thiosulfate sulfurtransferase 392
9624 Sarcosine dehydrogenase, mitochondrial precursor 115
Others
8437 Ubiquinol-cytochrome c reductase
iron-sulfur subunit, mitochondrial precursor
55
9537 Carbonic anhydrase 3 297The response of pancreatic proteins to ghrelin ad-
ministration were analyzed by 2-DE in order to get a
better understanding of the mechanisms involved in
the ghrelin-exocrine secretion through CCK signal. Eight
spots ranging from 6 to 200 kDa were detected differently
expressed in the pancreatic protein map (Figure 1). Onerat pancreas by ESI/Q-TOF MS






238.23 101578.9 Only Treatment
100.32 29427.2 Down
148.26 29412.7 Down
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compared with control group. One spot was found only
expressed in treatment group. These proteins were classi-
fied according to their functions (Table 2). Three down-
regulated proteins eukaryotic translation initiation factor
5A-1 (eIF5A), peroxiredoxin IV (PRx IV) and ubiquinol-
cytochrome c reductase (UQCR) were particular inter-
ested. eIF5A is involved in biosynthesis of pancreatic
enzyme by increasing plasma CCK level [20]. And this
data was different with ours. Judging by our reports,
ghrelin may affect on pancreatic exocrine secretion via
other factors as well as releasing CCK. Also, Yannick
demonstrated that UQCR and PRx IV down-regulated
biosynthesis of insulin related to diabetes [21]. Synthetically,
when the effects of exogenous ghrelin, given intraperitoneal
(i.p.) on pancreatic exocrine secretion, we have to consider
other factor like growth hormone related to insulin synthe-
sis as involving the CCK release and activation of choliner-
gic vago-vagal enteropancreatic reflex.
Conclusions
In conclusion, our result suggest a role of ghrelin on
pancreatic exocrine, but the protein concerning with
mechanism functional study was uncompleted. And
some following functional study of proteins will be done
in the near future.
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